Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CATX
CATX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CATX News
Perspective Therapeutics Prices $175M Public Offering to Advance Clinical Development
Feb 02 2026
seekingalpha
Perspective Therapeutics Raises $175 Million in Underwritten Offering
Feb 02 2026
Newsfilter
Oncolytics Biotech's Breakthroughs in Cancer Treatment
Jan 30 2026
Newsfilter
Perspective Therapeutics Updates VMT-α-NET Trial Results, 39% Patient Response Rate Achieved
Jan 09 2026
Globenewswire
Perspective Therapeutics CEO Thijs Spoor to Present at 2026 J.P. Morgan Healthcare Conference
Dec 18 2025
Globenewswire
Truist Securities Initiates Coverage on Perspective Therapeutics with a Buy Rating and Increases Price Target to $12
Nov 24 2025
Benzinga
UBS Reiterates Buy Rating for Perspective Therapeutics, Adjusts Price Target to $7
Nov 21 2025
Benzinga
Perspective Therapeutics to Attend Conferences Scheduled for December
Nov 20 2025
Newsfilter
Perspective Therapeutics Shares Latest Interim Results from Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at ESMO Congress 2025
Oct 20 2025
Newsfilter
BTIG Begins Coverage of Perspective Therapeutics with a Buy Rating and Sets Price Target at $14
Oct 10 2025
Benzinga
Perspective Therapeutics Doses First Patient with PSV359 in Phase 1/2a Study's Second Cohort for FAP-α Positive Solid Tumors
Oct 02 2025
Newsfilter
Top Analysts Recommend 3 Best Stocks to Purchase as of September 11, 2025
Sep 11 2025
TipRanks
Joel Sendek Takes Over as CFO of Perspective Therapeutics, Succeeding Juan Graham
Sep 04 2025
NASDAQ.COM
Perspective Therapeutics Reports Q2 Loss
Aug 13 2025
NASDAQ.COM
Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates
Aug 12 2025
NASDAQ.COM
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
Jul 24 2025
Newsfilter
Show More News
